

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Hepalink**

**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**

**(深圳市海普瑞藥業集團股份有限公司)**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 9989)**

## **VOLUNTARY ANNOUNCEMENT**

### **SETTLEMENT OF THE DISPOSAL OF SHARES OF KYMAB**

This is a voluntary announcement made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

Reference is made to the voluntary announcement of the Company dated January 11, 2021 (the “**Announcement**”) in relation to the disposal of 8,920,639 shares of Kymab Group Company Limited (“**Kymab**”) to Sanofi Foreign Participations BV, representing approximately 8.66% equity interest of Kymab (the “**Disposal**”). The board of the Company is pleased to announce that settlement of the Disposal took place on April 9, 2021.

The settlement of the aforementioned equity transfer was completed on April 9, 2021. The Group received the first tranche of transfer payment. After the completion of this settlement, the Group no longer holds equity in Kymab.

According to the requirements of equity transfer agreement, Sanofi FP BV will pay a total milestone consideration of no more than US\$350 million to all shareholders of Kymab based on the achievement of subsequent clinical progress milestone. The total amount and implementation time of the milestone consideration depends on the progress of the clinical trial of the new drug, which is uncertain. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board

**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**

**Li Li**

*Chairman*

Shenzhen, PRC

April 9, 2021

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Sun Xuan; the non-executive director of the Company is Mr. Bu Haihua; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.*